Earnings summaries and quarterly performance for INDIVIOR.
Research analysts who have asked questions during INDIVIOR earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for INDV
Also covers: AVDL, BFLY, BVS +17 more
David Amsellem
Piper Sandler Companies
4 questions for INDV
Also covers: ABBV, ALKS, AMGN +27 more
CG
Christian Glennie
Stifel
3 questions for INDV
PC
Paul Cuddon
Deutsche Numis
3 questions for INDV
Also covers: MXCT
Thibault Boutherin
Morgan Stanley
2 questions for INDV
Also covers: ALVO, EVO, GRFS +2 more
BF
Brandon Folkes
Rodman & Renshaw
1 question for INDV
Also covers: ACHV, ANIP, AVDL +10 more
BB
Brian Balchin
Jefferies
1 question for INDV
CB
Carl Byrnes
Northland Capital Markets
1 question for INDV
Also covers: ALVO, BLFS, BWAY +6 more
DD
Dennis Ding
Jefferies Financial Group Inc.
1 question for INDV
Also covers: ARDX, CARA, FOLD +5 more
Recent press releases and 8-K filings for INDV.
Indivior PLC Provides Full-Year 2026 Financial Guidance and Business Update
INDV
Guidance Update
Revenue Acceleration/Inflection
- Indivior PLC issued full-year 2026 financial guidance, projecting Total Net Revenue between $1,125 million and $1,195 million and Adjusted EBITDA between $535 million and $575 million.
- The company expects Total SUBLOCADE Net Revenue to reach $905 million to $945 million, reflecting 11% growth at the midpoint, driven by an acceleration of U.S. SUBLOCADE dispense unit growth to the mid-teens.
- Non-GAAP Operating Expenses are forecast to be $430 million to $450 million, benefiting from at least $150 million in annual savings due to a simplified operating model.
- Indivior anticipates 35% Adjusted EBITDA growth and a 14 percentage point expansion in Adjusted EBITDA margin to 48% in 2026, as it enters Phase II of its Action Agenda focused on acceleration.
3 days ago
Indivior Announces Positive Clinical Trial Results for SUBLOCADE
INDV
Product Launch
- Indivior PLC announced that a clinical trial published in JAMA Network Open showed its SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence in individuals with moderate-to-severe opioid use disorder (OUD).
- Both the 100-mg and 300-mg monthly maintenance doses were well-tolerated with no new safety signals identified.
- Post-hoc analyses indicated that the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.
Dec 17, 2025, 4:30 PM
Indivior PLC Shareholders Approve Scheme of Arrangement and Corporate Restructuring
INDV
M&A
Proxy Vote Outcomes
Delisting/Listing Issues
- On December 11, 2025, Indivior PLC shareholders approved amended and restated articles of association to facilitate a Scheme of Arrangement.
- This Scheme of Arrangement will result in Indivior PLC becoming a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc., with all Indivior PLC shareholders becoming shareholders of Indivior Pharmaceuticals, Inc..
- Shareholders overwhelmingly approved the Scheme of Arrangement at a Court Meeting, with 94,968,161 votes for and 46,544 votes against.
- At an Extraordinary General Meeting on the same date, shareholders also passed all related special resolutions, including authorizing the reduction of share capital, issuance of new shares, and the re-registration of the company as a private company limited by shares.
- The completion of the Scheme of Arrangement remains subject to the sanction of the High Court of Justice, with a hearing anticipated on January 22, 2026.
Dec 15, 2025, 9:04 PM
Indivior Outlines Strategic Vision and Cost Optimization Initiatives
INDV
Management Change
Guidance Update
New Projects/Investments
- Indivior has implemented an "Indivior Action Agenda" to maximize business value, including a $150 million reduction in OPEX and a commitment that 2026 OPEX will not exceed $450 million. This is expected to lead to significant margin improvement in 2026.
- The company is optimizing its international business by reducing its presence from 41 countries to 4 countries (Canada, Australia, France, Germany), which represent 77% of forecasted net revenue and 94% of forecasted EBITDA for the Rest of World business.
- Commercial support for OPVEE has been ceased due to unfavorable market dynamics, allowing for greater focus on maximizing the core asset, SUBLOCADE.
- A significant untapped opportunity exists for SUBLOCADE in commercially covered patients, who represent 60% of covered lives but only 25% of prescriptions. Indivior plans aggressive investment in consumer (DTC) efforts to drive long-acting injectable market penetration, currently at 8%.
- Indivior's R&D pipeline includes Indivior 6001 and Indivior 2000 with phase two data readouts expected in early Q2 2026. Future M&A will target commercial stage assets with $200 million+ peak sales potential in adjacent therapeutic areas.
Dec 2, 2025, 8:30 PM
Indivior Outlines Strategic Vision, Cost Optimization, and SUBLOCADE Growth Initiatives
INDV
Guidance Update
New Projects/Investments
M&A
- Indivior has implemented an "Action Agenda" to maximize business value, which includes removing $150 million of OPEX and targeting 2026 OPEX not exceeding $450 million.
- The company is optimizing its Rest of World business, reducing its presence from 41 countries to 4 (Canada, Australia, France, and Germany), which collectively represent 77% of forecasted net revenue and 94% of forecasted EBITDA.
- Commercial support for OPVEE has been discontinued due to market dynamics and lack of synergy with the SUBLOCADE business.
- Indivior is prioritizing investment in SUBLOCADE, which has 88% payer access and a market share stabilized in the mid-70%, with plans for aggressive consumer campaigns to drive long-acting injectable penetration.
- Future growth will also involve commercial stage acquisitions with over $200 million peak sales potential in adjacent therapeutic areas.
Dec 2, 2025, 8:30 PM
Indivior Concludes Legacy U.S. Department of Justice Matter
INDV
Legal Proceedings
- Indivior PLC announced on November 20, 2025, the conclusion of its legacy U.S. Department of Justice (DOJ) matter.
- The company resolved the matter by paying the outstanding obligation of $295 million.
- This payment was funded with Indivior's cash on hand, leading to the termination of the resolution agreement with the DOJ.
- CEO Joe Ciaffoni stated that this action removes a significant liability and simplifies the company's capital structure.
Nov 20, 2025, 9:01 PM
Indivior PLC to Redomicile to U.S. with New Nasdaq-Listed Holding Company
INDV
Delisting/Listing Issues
M&A
Proxy Vote Outcomes
- Indivior PLC is undergoing a redomiciliation from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc., a new Delaware corporation, as its ultimate holding company.
- Under the scheme, Indivior Shareholders will receive one Indivior Pharmaceuticals Share for every one Indivior Share held.
- The new Indivior Pharmaceuticals Shares will be listed on Nasdaq, with trading anticipated to commence at the end of January 2026, following the expected effective date of the Scheme.
- The strategic move aims to maximize the benefits of the Group's U.S. stock listing, including expanding U.S. capital markets presence, increasing U.S. equity indexation, and simplifying corporate governance.
- Post-redomiciliation, Indivior Pharmaceuticals will comply with U.S. corporate governance standards, and the U.K. City Code on Takeovers and Mergers will no longer apply.
Nov 14, 2025, 2:05 PM
Indivior discusses Q3 results, Sublocade growth, and cost savings
INDV
Guidance Update
Layoffs
New Projects/Investments
- Indivior reported a strong Q3 beat and raise, with Sublocade showing 10% growth this year, and announced $150 million in cost savings for next year, reducing OPEX to no more than $450 million.
- The company expects Sublocade sales to surpass $1 billion, with current year guidance of $825 million-$845 million, and aims to increase long-acting injectable (LAI) penetration from 8% to 20-30%.
- The $150 million cost savings include a 30% reduction in headcount and the discontinuation of non-essential spend and certain product/market activities.
- Indivior plans to acquire new commercial stage assets with potential revenue of at least $200 million and has a history of $400 million in share buybacks.
Nov 13, 2025, 1:40 PM
Indivior Discusses Strong Q3 Results, SUBLOCADE Growth, and Cost Savings at Stifel Conference
INDV
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Indivior reported strong Q3 results, marking its second consecutive beat and raise, with the stock reaching a seven-year high.
- The company upgraded its 2025 guidance for SUBLOCADE to $825 million-$845 million and anticipates the product will eventually surpass $1 billion in sales.
- Indivior announced $150 million in cost savings for next year, targeting OpEx of no more than $450 million, primarily through a headcount reduction of over 30% and discontinuing non-essential spend.
- The company is executing its "Indivior Action Agenda," focusing on generating momentum in 2025 and accelerating growth in 2026, with an expected pickup in SUBLOCADE's growth rate and immediate bottom-line acceleration.
- Indivior is exploring M&A opportunities for commercial-stage assets with potential revenues of at least $200 million in new therapeutic areas, and has a history of returning capital to shareholders through buybacks.
Nov 13, 2025, 1:40 PM
Indivior Reports Strong Q3 Results, Announces $150 Million Cost Savings, and Sublocade Growth Expectations
INDV
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Indivior reported a strong Q3 beat and raise, marking its second consecutive quarterly beat and raise, with the stock reaching a seven-year high.
- The company announced $150 million in cost savings for next year, reducing OPEX to no more than $450 million and expecting EBITDA margins to increase from the mid-30s to the mid-40s.
- Sublocade is guided for 10% growth this year, with revenue growth and accelerated bottom-line growth expected in 2026, and is anticipated to eventually surpass $1 billion in sales.
- Indivior plans to pursue commercial stage assets for future growth, targeting products with at least $200 million in potential revenue.
Nov 13, 2025, 1:40 PM
Quarterly earnings call transcripts for INDIVIOR.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more